Stayble Therapeutics AB
STABL | ST
Overview
Corporate Details
- ISIN(s):
- SE0013513652 (+1 more)
- LEI:
- 549300WD23DE1US21868
- Country:
- Sweden
- Address:
- Lennart Torstenssonsgatan 6, 412 56 Göteborg
- Website:
- https://staybletherapeutics.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Stayble Therapeutics AB is a clinical-stage pharmaceutical company focused on developing treatments for disc-related spinal disorders. The company's lead drug candidate, STA363, is an injectable, minimally invasive therapy designed for patients suffering from lumbar disc herniation (LDH) who have not found relief from conservative treatments like analgesics and physical therapy. STA363 aims to bridge the therapeutic gap between conservative care and surgery by offering a simple and efficient second-line treatment option. The company is currently advancing STA363 through Phase 1b clinical trials with the objective of becoming a market leader in its niche.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Stayble Therapeutics AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Stayble Therapeutics AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Stayble Therapeutics AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
